ABUS Up On HBV Trial Data, VIR's COVID-19 Therapies On Track, All Eyes On DVAX

Today's Daily Dose brings you news about positive results from Arbutus' HBV trial; encouraging phase I results of Moderna's COVID-19 vaccine candidate; biotech stocks hitting new highs and Vir Biotechnology's progress in the battle against the novel coronavirus.

from RTT - Biotech https://ift.tt/3bLlp93
via IFTTT